Four-Pronged attack on stomach cancer tested before surgery
NCT ID NCT07151209
Summary
This study is testing a combination of two immunotherapy drugs, one targeted therapy drug, and a standard chemotherapy regimen. The goal is to see if this four-drug combination can shrink tumors enough to allow for surgical removal in patients with a specific type of advanced stomach or gastroesophageal (GE) junction cancer. It is for patients who have not yet received treatment for their advanced cancer and whose tumors have specific genetic features (MSI-H/dMMR).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.